RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced a strategic license agreement with Eli Lilly and Company (“Lilly”). This collaboration will enable Lilly to utilize Sangamo’s innovative and proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB. Preclinical studies in nonhuman primates have demonstrated STAC-BBB’s significant ability to penetrate the blood-brain barrier and transduce neurons effectively. The agreement provides Lilly with an exclusive worldwide license for the STAC-BBB capsid, initially for one therapeutic target, with the option to include up to four additional targets upon payment of further license fees. Lilly intends to employ this advanced delivery technology for its intravenously administered genomic medicines aimed at treating specific diseases of the central nervous system.
Sandy Macrae, Chief Executive Officer of Sangamo, commented, “STAC-BBB represents a potential breakthrough in addressing the persistent challenges of delivering therapies to the central nervous system. We are excited to partner with Lilly to leverage the capabilities of STAC-BBB in developing new treatments for neurological diseases where significant patient needs remain unmet. This agreement, our third since unveiling STAC-BBB in March 2024, underscores the strong and continuing interest in our novel capsid delivery platform within the pharmaceutical industry.”
The terms of the agreement outline Sangamo’s responsibility for the technology transfer of the STAC-BBB capsid. Lilly will then assume full responsibility for all subsequent stages, including research, preclinical and clinical development, regulatory affairs, manufacturing, and the global commercialization of any resulting gene therapy products. Sangamo will receive an $18 million upfront license fee from Lilly and is eligible for potential future payments including up to $1.4 billion in licensed target fees and milestone payments across the five potential neurology disease targets, as well as tiered royalties on future net sales of any resulting products, with certain specified adjustments.
https://www.businesswire.com/news/home/20250403023818/en/Sangamo-Therapeutics-Announces-Capsid-License-Agreement-With-Lilly-to-Deliver-Genomic-Medicines-for-Diseases-of-the-Central-Nervous-System
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
